Table 6.
Antiviral activity of UDA against SARS-CoV replication in Vero 76 cells when added to cells at various times before and after virus exposure to cells.
| Treatment | Neutral red (NR) uptake assay |
Virus yield reduction assay |
|||
|---|---|---|---|---|---|
| IC50a (μg/ml) | CC50b (μg/ml) | SIc | IC90d (μg/ml) | Virus yield | |
| Pre-treatment (1 h) | 0.51 ± 0.09 | 5.30 ± 0.40 | 10.63 ± 2.12 | 0.05 ± 0 | 4.6 ± 0.4 |
| Post-treatment (1 h) | 1.80 ± 0.35 | 6.70 ± 0.66 | 3.87 ± 1.02 | 2.4 ± 0.7 | 4.2 ± 0.5 |
| Post-treatment (4 h) | 1.43 ± 0.15 | >10.0 ± 0 | 7.03 ± 0.7 | ND | ND |
| Post-treatment (24 h) | >10.0 ± 0 | >10.0 ± 0 | 0 ± 0 | ND | ND |
| Virus-treatment (1 h) | 0.53 ± 0.24 | 5.80 ± 0.36 | 12.20 ± 4.26 | 0.4 ± 0 | 4.7 ± 0.2 |
a
50% virus inhibitory concentration.
b
50% cell cytotoxic concentration of drug.
c
Selective index: SI = CC50/IC50.
d
90% virus inhibitory concentration.